King's College London s.lovestone@iop.kcl.ac.uk
Centre for Imaging and Biomarkers (completed)
Leadership
Professor Simon Lovestone
Members
Programme Management Group and pilot project leads
Dr Alison Campbell King’s College London
Dr Ian Pike Proteome Sciences
Edwina Wright Programme Consultant
Dr David Parry South East Health Trust Association
Professor Dave Hawkes Imaging working party; University College London
Professor Chris Lowe ‘omics working party; Cambridge
Professor Graham Lord Informatics working party; Imperial College, London
Dr Christina Legido-Quigley Metabonomics of dementia project; King’s College London
Professor Jeremy Nicholson Metabonomics of dementia project; Imperial College London
Professor Shitij Kapur Markers of schizophrenia project; King’s College London
Professor Sabine Bahn Markers of schizophrenia project; Cambridge
Professor Nick Fox Multi-site neuroimage management project; Institute of Neurology
Professor Peter Jezzard Multi-site neuroimage management project; FRIMB Centre, John Radcliffe Hospital
Professor Derek Hill Multi-site neuroimage management project; Ixico
Colleagues from Lilly UK, Pfizer and GSK provided input into project development as below:
Dr Chas Bountra GlaxoSmithKline
Dr Jackie Hunter GlaxoSmithKline
Dr David Bowman Lilly
Dr Andrew Wood Lilly
Dr Mike Hutton Lilly
Dr Ruth McKernan Pfizer
Related news
Centre for Imaging and Biomarkers progress update
A business plan is under discussion to provide a Centre for Imaging and Biomarkers (CIB) of global significance, to advance the development of personalised medicine in drug development and in clinical practice.
30 Oct '09Established methods of drug development have become less productive in delivering highly effective and safe new medicines, particularly for diseases such as neurodegenerative disorders and cancer. One of the main obstacles is the paucity of biomarkers for use in clinical trials as markers of toxicity, disease response or as surrogate endpoints. At the same time, physicians require better diagnostic tools to identify early signs of disease, at a point when early intervention and treatment is likely to be more successful. Looking ahead, biomarkers are the essential component of the anticipated era of personalised medicine.
The Programme team organized a highly successful conference entitled “Biomarkers in Brain Disease” in collaboration with The New York Academy of Science which was held in January 2009 in Oxford, UK. Proceedings were published in the Annals of the New York Academy of Science (2009): volume 1180 (editor Professor Simon Lovestone, Director NIHR Biomedical Research Centre for Mental Health, King’s College London).
The team conducted a scoping exercise and developed an outline business plan for the creation of a Centre for Imaging and Biomarkers (CIB), which would build on existing partnerships between universities, hospitals, pharmaceutical and diagnostic companies.
The Programme team’s activities helped to develop thinking around potential technical and organization solutions for biomarker research and, even though the CIB proposal per se was not taken forward for implementation, the themes developed have been influential in shaping other initiatives, for example the creation of Imanova Ltd